Leveraging Biomedical and Healthcare Data

Dr. Kobeissy is a Professor at the Department of Neurobiology at Morehouse School of Medicine, Atlanta, Ga. Dr. Kobeissy’s research involves investigating biomarkers of brain injury and mechanisms of neural death. In this area, Dr. Kobeissy utilizes advanced multidimensional neuroproteomics/systems biology platforms to investigate biomarker change. Dr. Kobeissy is the author of more than 250 publications along with two patents. He is the editor of several books on biomarkers and proteomics; he serves on several national and international study sections including the NIIH, DoD, and the VA. He is the associate director of the Center of Neuroproteomics and Biomarker Research. Dr. Kevin Wang is internationally recognized for his original contributions to the fields of traumatic brain injury (TBI)-linked proteolytic enzymes, therapeutic targets, neuroproteomics/systems biology, biomarker discovery and validation. Dr. Wang has published in the areas of systems biology/bioinformatics of biomarkers identification in with the main application on neural injury. In his quest for brain injury therapeutics, his omics/systems biology work has led to the identification of clinical diagnostic utility for two brain injury protein biomarkers during the acute phase of brain injury which have now been confirmed tested in clinical samples and are now moving forward to FDA-approval seeking pivotal clinical study. His current research directions include studying mechanisms for CNS injury, neuroproteomics, systems biology, and substance abuse-induced brain perturbation using systems biology approach. He has published more than 200 peer-reviewed papers, reviews and book chapters and co-authored eight US patents and co-edited four books. Dr. Wang is also past President (2011-12) and current Councilor (2013 - present) of the National Neurotrauma Society (USA). Dr. Fadi Zaraket obtained his PhD in the ECE from UT Austin. Dr. Zaraket worked in the industry for a dozen years at IBM, Sun Microsystems, and Santa Cruz Operations. His current research spans the (1) automated correctness and (2) information extraction areas. He teaches programming and computer engineering courses. His current research involves extracting entities and relational associations from related text documents, aggregating the extracted entities into graph entities using cross-document analysis techniques, and analyzing the graph entities for domain specific insight. The application of this approach to medical publications in the area of brain diseases with focus on stroke, brain injury and spinal cord injury led to several discoveries. The approach was also applied to Arabic documents coupled with computational linguistic based features to extract information from several corpora such as temporal entities from news documents, narrator chain from literature documents, and family relations from biblical and Islamic tradition documents. Dr. Fadi published in the areas of verification of logic systems and information extraction in several renowned peer reviewed conferences and journals. Ali Alawieh’s research is focused on developing translational and site-targeted immunotherapeutics for stroke and brain injury. His research involves a complex mix of in-silico, in-vitro and in-vivo analyses of dysregulated protein and gene-regulatory networks after CNS injury, and how these networks could be fine-tuned to reduce injury and allow recovery. Ali has contributed to novel tools and approaches in data mining, computational modeling and network analysis including among others an automated and intelligent extraction system (SAMNA) to curate protein dysregulation data from scientific literature, a machine learning-based approach for prediction and analysis of bacterial resistance progression in Europe, and a novel approach for constructing and leveraging disease-related protein interaction networks. Ali has published his work in several peer-reviewed journals and wrote several book chapters and reviews in the fields of systems biology, data mining, and computational modelling.

• Part I Understanding Molecular Architecture of Disease Using Big Data1. Curation of molecular data pertaining to human cancer and the Cancer Genome Atlas Initiative 2. Merging data from published literature to understand the sequence of disease pathology 3. Predicting potential therapeutic targets using drug-gene and gene-disease associations 4. Combination of graph theory and big data analysis in genomics and proteomics 5. Challenges in sharing, standardization and dissemination of molecular big dataPart II Guiding Health Care Decisions Using Big Data6. Towards a unified version of EMR corpora and data systems7. Natural language processing and computational linguistics in EMR analysis8. Orienting infectious disease management using Big Data9. Modeling disease burden using big data10. Automated diagnosis and risk factor prediction based on natural language processingPart III Online Repositories and In-Silico Research in the Era of Big Data11. Curating a brain connectome using Big Data12. Genotype and phenotype associations using online clinical repositories – a step-wise approach13. In-silico pharmacology and cost- and time- effective approaches in drug discovery14. Guided and semi-automatic approaches for clinical meta-analyses15. Towards a unified language in molecular big data